This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2009 Mar;10(3):204-5.

doi: 10.1016/S1470-2045(09)70051-8.

Targeting the future in head and neck cancer

PMID: 19261251
DOI: 10.1016/S1470-2045(09)70051-8

Comment

Targeting the future in head and neck cancer

David M Brizel. Lancet Oncol. 2009 Mar.

. 2009 Mar;10(3):204-5.

doi: 10.1016/S1470-2045(09)70051-8.

Author

PMID: 19261251
DOI: 10.1016/S1470-2045(09)70051-8

No abstract available

PubMed Disclaimer

Comment on

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE. Cohen EE, et al. Lancet Oncol. 2009 Mar;10(3):247-57. doi: 10.1016/S1470-2045(09)70002-6. Epub 2009 Feb 7. Lancet Oncol. 2009. PMID: 19201650 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information